Zomig (zolmitriptan) is used for the treatment of migraines with or without aura (warning signs that occur prior to the onset of a migraine). Zomig is not to be used for the prevention of migraine. Migraine headaches are thought to be caused by a widening of the blood vessels in the head. Zolmitriptan belongs to a class of drugs known as 5-hydroxytryptamine agonists that relieve migraine headaches by narrowing these blood vessels.
In most patients, Zomig eliminates or reduces the symptoms of migraine including headache, nausea, vomiting, and sensitivity to light and sound.
Zomig comes as a tablet, 2.5 mg., to take by mouth.
The recommended single adult dose is 2.5 mg. If the migraine headache returns, the dose may be repeated after 2 hours. A total dose of 10 mg should not be exceeded in any 24-hour period. If a dose has not helped a headache, do not take a second dose without first consulting a doctor.
Zomig tablets should be taken whole with water at the first sign of a migraine headache, but they can be taken at any time during a migraine headache.
Zomig should not be used by anyone who is allergic to zolmitriptan or any of the components of the formulation, or has heart disease, angina, blood vessel disease, severe or uncontrolled high blood pressure or has had a heart attack.
Before taking Zomig you may not have taken ergotamine-containing, ergot-type medications or another 5-hydroxytryptamine agonist in the previous 24 hours. Neither may you have taken monoamine oxidase (MAO) inhibitors within the past 2 weeks.
Rare, severe allergic reactions to zolmitriptan may occur. Because of the possibility of allergic reaction, people who are allergic to any of the other drugs of this class (5-hydroxytryptamine agonists) should not use Zomig.
Very rarely, some people without recognized heart disease may have serious heart-related problems. So, if you think you may have risk factors for heart disease such as smoking, high blood pressure, high cholesterol, or family history of heart disease, or if you are pregnant, nursing, or taking medication, talk to your health care professional before taking Zomig.
Zomig should not be used by individuals with hemiplegic or basilar migraine. Zomig should not be used by individuals to whom unrecognized coronary artery disease (CAD) is predicted by risk factors unless a cardiovascular evaluation provides satisfactory clinical evidence that the individual is reasonably free of coronary artery and ischemic myocardial disease or other significant underlying cardiovascular disease.
Do not use Zomig if you are pregnant, think you might by pregnant, are trying to be pregnant, or are not using adequate contraception, unless you have discussed this with your doctor.
Possible side effects
The most common side effects associated with taking Zomig (zolmitriptan) include dizziness, tightness, pressure, pain in the neck, throat, or jaw, fatigue, tingling, drowsiness or nausea.
If you notice other effects not listed above, contact your doctor.
There is no clinical experience with an overdose of Zomig (zolmitriptan).
If overdose of Zomig is suspected, contact your local poison control center or emergency room immediately.
Keep Zomig in a tightly closed container and out of reach of children. Store Zomig at room temperature and away from excess heat and moisture (not in the bathroom).
For more information about Zomig, please visit Zomig.com.
The above information is intended to supplement, not substitute for, the expertise and judgment of your physician, or other healthcare professional. It should not be construed to indicate that use of Zomig is safe, appropriate, or effective for you.
Consult your health care professional before you